Core Viewpoint - Aurinia Pharmaceuticals reported strong second-quarter 2025 earnings, exceeding revenue and earnings expectations, and raised full-year guidance, indicating positive business momentum and effective cost management [1][13]. Financial Performance - Q2 2025 revenue reached $70.0 million, surpassing the $63.8 million estimate by 9.7%, and increased by 22.2% from $57.2 million in Q2 2024 [2][5]. - Diluted EPS (GAAP) was $0.16, slightly above the $0.15 estimate, and a significant increase from $0.01 in Q2 2024, reflecting a 1,500% year-over-year growth [2][7]. - Net income (GAAP) rose to $21.5 million from $0.7 million in the prior year, marking a 2,971.4% increase [2][7]. - Operational cash flow for the first half of 2025 was $45.5 million, a turnaround from an outflow in the same period of 2024 [8]. Product and Market Focus - Aurinia specializes in therapies for autoimmune diseases, particularly lupus nephritis, with its main product being LUPKYNIS, which is now recommended as a first-line treatment [3][5]. - The company’s revenue growth is primarily driven by LUPKYNIS, supported by updated treatment guidelines from the American College of Rheumatology [5]. - LUPKYNIS is approved in multiple regions, including the U.S., Europe, and Japan, with a notable 55% increase in license and collaboration revenue to $3.4 million [6]. Cost Management and Efficiency - Selling, general, and administrative expenses decreased significantly from $44.9 million in Q2 2024 to $26.0 million in Q2 2025, attributed to lower personnel costs and improved operational efficiency [7]. - The company is on track for approximately $40 million in annualized savings following a restructuring in November 2024 [8]. Shareholder Returns - In the first half of 2025, Aurinia repurchased 11.2 million shares for $90.8 million, with a total of 18.3 million shares repurchased since the buyback program began [10]. - The board authorized a $150 million increase in the buyback plan, reflecting a commitment to returning capital to shareholders [10]. Future Outlook - Management raised full-year revenue guidance to between $260 million and $270 million, up from the previous range of $250 million to $260 million, indicating confidence in ongoing commercial trends [13]. - The lead candidate AUR200 is progressing with positive Phase 1 data and plans for further clinical trials later in 2025 [9].